Quince Therapeutics, Inc. (QNCX) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in Capital, Common StockUSD (m); Additional Paid in CapitalUSD $460.45M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $14.00K; Additional Paid in Capital, Common StockUSD (m); Additional Paid in CapitalUSD $435.59M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $0.00; Additional Paid in Capital, Common StockUSD (m); Additional Paid in CapitalUSD $418.99M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $54.00K; Additional Paid in Capital, Common StockUSD (m); Additional Paid in CapitalUSD $415.70M.
Quince Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $1.00K | (m) | $460.45M | $4.25M | $-500.03M | $-35.32M | 3 month · $12.09M 6 month · $13.38M |
| 2026-03-31 | $0.00 | $14.00K | (m) | $435.59M | $4.61M | $-424.54M | $15.67M | 3 month · $1.29M |
| 2025-12-31 | $0.00 | $0.00 | (m) | $418.99M | $5.75M | $-460.45M | $-35.71M | 12 month · $5.11M |
| 2025-09-30 | $0.00 | $54.00K | (m) | $415.70M | $6.29M | $-420.99M | $1.06M | 3 month · $1.25M 9 month · $3.91M |
| 2025-06-30 | $0.00 | $53.00K | (m) | $413.08M | $6.16M | $-407.55M | $11.74M | 3 month · $1.27M 6 month · $2.66M |
| 2025-03-31 | $0.00 | $44.00K | (m) | $408.08M | $1.96M | $-391.50M | $18.58M | 3 month · $1.39M |
| 2024-12-31 | $0.00 | $44.00K | $406.61M | $406.61M | $-35.00K | $-376.47M | $30.15M | 12 month · $4.75M |
| 2024-09-30 | $0.00 | $43.00K | $405.48M | (m) | $3.42M | $-364.01M | $44.93M | 3 month · $1.12M 9 month · $3.62M |
| 2024-06-30 | $0.00 | $43.00K | $404.36M | (m) | $1.09M | $-358.52M | $46.97M | 3 month · $1.22M 6 month · $2.50M |
| 2024-03-31 | $0.00 | $43.00K | $403.10M | (m) | $1.82M | $-330.79M | $74.18M | 3 month · $1.27M |
| 2023-12-31 | $0.00 | $43.00K | $401.64M | (m) | $3.05M | $-319.64M | $85.08M | 12 month · $5.22M |
| 2023-10-20 | (m) | $6.50M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | $36.00K | $393.33M | (m) | $516.00K | $-310.75M | $83.13M | 3 month · $1.33M 9 month · $4.13M |
| 2023-06-30 | $0.00 | $36.00K | $391.99M | (m) | $257.00K | $-305.40M | $86.88M | 3 month · $1.32M 6 month · $2.80M |
| 2023-03-31 | $0.00 | $36.00K | $390.64M | (m) | $38.00K | $-300.51M | $90.20M | 3 month · $1.48M |
| 2022-12-31 | $0.00 | $36.00K | $389.11M | (m) | $-289.00K | $-288.26M | $100.59M | 12 month · $16.62M |
| 2022-09-30 | $0.00 | $36.00K | $387.47M | (m) | $-253.00K | $-282.73M | $104.53M | 3 month · $694.00K 9 month · $14.99M |
| 2022-06-30 | $0.00 | $36.00K | $386.77M | (m) | $-466.00K | $-274.80M | $111.53M | 3 month · $5.05M 6 month · $14.29M |
| 2022-03-31 | $0.00 | $30.00K | $365.10M | (m) | $-506.00K | $-258.24M | $106.38M | 3 month · $9.24M |
| 2021-12-31 | $0.00 | $30.00K | $355.23M | (m) | $-79.00K | $-236.60M | $118.59M | 12 month · $29.85M |
| 2021-09-30 | (m) | $30.00K | $345.75M | (m) | $71.00K | $-213.20M | $132.65M | 3 month · $7.62M 9 month · $21.36M |
| 2021-06-30 | (m) | $30.00K | $333.43M | (m) | $117.00K | $-191.49M | $142.08M | 3 month · $6.75M 6 month · $13.74M |
| 2021-03-31 | (m) | $29.00K | $326.01M | (m) | $189.00K | $-169.74M | $156.48M | 3 month · $6.99M |
| 2020-12-31 | (m) | $29.00K | $318.57M | (m) | $313.00K | $-146.65M | $172.26M | 12 month · $14.47M |
| 2020-09-30 | (m) | $29.00K | $313.57M | (m) | $513.00K | $-126.10M | $188.01M | 3 month · $4.16M 9 month · $9.51M |
| 2020-06-30 | (m) | $29.00K | $309.32M | (m) | $711.00K | $-104.59M | $205.47M | 3 month · $3.40M 6 month · $5.35M |
| 2020-03-31 | (m) | $29.00K | $305.03M | (m) | $-37.00K | $-86.98M | $218.04M | 3 month · $1.96M |
| 2019-12-31 | (m) | $27.00K | $185.20M | (m) | $60.00K | $-69.81M | $115.48M | 12 month · $2.06M |
| 2019-09-30 | (m) | $27.00K | $184.59M | (m) | $96.00K | $-57.43M | $127.29M | 3 month · $912.00K 9 month · $1.48M |
| 2019-06-30 | (m) | $27.00K | $183.68M | (m) | $80.00K | $-47.57M | $136.22M | 3 month · $377.00K 6 month · $567.00K |
| 2019-03-31 | (m) | $4.00K | $498.00K | (m) | $-23.00K | $-38.51M | $-38.03M | 3 month · $190.00K |
| 2018-12-31 | (m) | $3.00K | $245.00K | (m) | $-49.00K | $-32.83M | $-32.63M | 12 month · $155.00K |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | $-29.25M | 3 month · $20.00K 9 month · $47.00K |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | $-26.74M | 3 month · $14.00K 6 month · $27.00K |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | $-23.64M | 3 month · $13.00K |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $-20.28M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |